XTX Topco Ltd Purchases 26,034 Shares of ABVC BioPharma, Inc. (NASDAQ:ABVC)

XTX Topco Ltd increased its position in ABVC BioPharma, Inc. (NASDAQ:ABVC) by 75.7% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 60,439 shares of the company’s stock after purchasing an additional 26,034 shares during the period. XTX Topco Ltd owned approximately 0.36% of ABVC BioPharma worth $64,000 at the end of the most recent quarter.

ABVC BioPharma Trading Up 8.6%

Shares of NASDAQ:ABVC opened at $3.30 on Friday. The stock’s fifty day simple moving average is $2.81 and its two-hundred day simple moving average is $1.56. ABVC BioPharma, Inc. has a 1-year low of $0.40 and a 1-year high of $5.48. The stock has a market cap of $56.03 million, a PE ratio of -19.41 and a beta of 0.27.

ABVC BioPharma (NASDAQ:ABVC) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.13) earnings per share for the quarter. ABVC BioPharma had a negative net margin of 963.46% and a negative return on equity of 46.76%.

ABVC BioPharma Company Profile

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.